Growth factors and other targets for rational application as intervention agents.
Mulshine
J L
JL
Biomarkers and Prevention Research Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Birrer
M
M
Treston
A M
AM
Scott
F
F
Quinn
K
K
Avis
I
I
Cuttitta
F
F
D016588:Anticarcinogenic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D015195:Drug Design; D005260:Female; D019886:Gastrin-Releasing Peptide; D006133:Growth Substances; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D015474:Isotretinoin / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008297:Male; D016609:Neoplasms, Second Primary / Q000517:prevention & control; D009857:Oncogenes; D010455:Peptides / Q000037:antagonists & inhibitors; D012189:Retrospective Studies; D013183:Sputum / Q000166:cytology; D013629:Tamoxifen / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology
D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D006133:Growth Substances; D010455:Peptides; D013629:Tamoxifen; D019886:Gastrin-Releasing Peptide; D015474:Isotretinoin